J Benjamin Matheny, PA
Medical · Kokomo, INNPI 1255325098
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,677, more than ten times the $85 reported in 2021.
Across 359 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$890
- AbbVie$730
- Novo Nordisk$481
- Pfizer$470
- Lilly USA, LLC$410
- Bayer$384
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,724100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $890 |
| AbbVie | 59 | $730 |
| Novo Nordisk | 40 | $481 |
| Pfizer | 25 | $470 |
| Lilly USA, LLC | 26 | $410 |
| Bayer | 28 | $384 |
| GSK | 22 | $335 |
| Amgen | 16 | $282 |
| Axsome Therapeutics, Inc. | 8 | $216 |
| Abbott | 11 | $212 |
| Dexcom, Inc. | 8 | $142 |
| Biohaven Pharmaceutical Holding Company Ltd. | 9 | $141 |
| Astellas Pharma US Inc | 9 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $99 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $86 |
| Phathom Pharmaceuticals, Inc. | 8 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $75 |
| Boehringer Ingelheim | 5 | $74 |
| Lundbeck LLC | 4 | $65 |
| Ironwood Pharmaceuticals, Inc | 4 | $57 |
| Edwards Lifesciences | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Antares Pharma, Inc. | 2 | $28 |
| Novartis | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Medtronic | 1 | $22 |
| Corium, LLC | 1 | $21 |
| Merck | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Shield Therapeutics Inc | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Biohaven Pharmaceuticals, Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Almatica Pharma LLC | 1 | $15 |
How this compares
$5,724 in reported general payments places this provider in the 85th percentile of 273 medical providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $84,285 |
| JardianceEmpagliflozin | 47 | $53,805 |
| TrulicityDulaglutide | 43 | $50,240 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $41,177 |
| JanuviaSitagliptin Phosphate | 39 | $36,926 |
| OzempicSemaglutide | 22 | $34,550 |
| XareltoRivaroxaban | 15 | $19,460 |
| FarxigaDapagliflozin Propanediol | 21 | $16,808 |
| EliquisApixaban | 23 | $16,405 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 21 | $14,743 |
| EntrestoSacubitril/Valsartan | 14 | $14,527 |
| LinzessLinaclotide | 12 | $10,191 |
| TrintellixVortioxetine Hydrobromide | 11 | $10,010 |
| Bydureon BciseExenatide Microspheres | 11 | $8,957 |
| MyrbetriqMirabegron | 11 | $6,718 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $410 | $134,525112 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $74 | $68,54868 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $335 | $47,19372 claims |
| MerckJanuvia | $19 | $36,92639 claims |
| Novo NordiskOzempic | $481 | $34,55022 claims |
| Johnson & JohnsonXarelto | $16 | $19,46015 claims |
| AstraZenecaFarxiga | $890 | $16,80821 claims |
| PfizerEliquis | $470 | $16,40523 claims |
| NovartisEntresto | $28 | $14,52714 claims |
| AbbVieLinzess | $730 | $10,19112 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $99 | $10,01011 claims |
| Astellas Pharma US IncMyrbetriq | $129 | $6,71811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 273 medical providers in Indiana.
Other medical in Kokomo
- Meggie BeckleyIndianapolis$125K
- Jennifer ConnerIndianapolis$98K
- Brandon BoydCarmel$46K
- Karey DavisNew Castle$45K
- Sheryl NewCarmel$39K
- Lindsey GradyValparaiso$39K
- Jennifer IrwinIndianapolis$34K
- Dennae DaltonZionsville$33K
- Jenifer FortneyFort Wayne$26K
- Jordan Stemer-MirandaCrown Point$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.